NASDAQ OMX

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

18.4.2017 14:00 | NASDAQ OMX

Dela
  • RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once granted
  • BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal indications 
  • Top-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017
  • A Phase II study with BEKINDA® 12 mg for diarrhea-predominant irritable bowel syndrome (IBS-D) is ongoing, with top-line results expected in the third quarter of 2017
  • RedHill will host an R&D Day and live webcast on BEKINDA® on Thursday, April 27, 2017 in NYC, discussing the product, indications, potential markets and the ongoing Phase III and II studies for acute gastroenteritis and IBS-D, respectively

TEL-AVIV, Israel, April 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has received notices of allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102)1. Once granted, the patents are expected to be valid until at least 2034.

Danielle Abramson, Ph.D., RedHill's Director of Intellectual Property & Research said: "We are very pleased with the allowance of two additional U.S. patents for BEKINDA®. This is an important addition to RedHill's strong IP portfolio, that will further enhance our protection of BEKINDA®. We are approaching significant milestones with BEKINDA® in the coming months, with top-line results from the Phase III study for gastroenteritis and gastritis expected in the second quarter of 2017 and top-line results from the Phase II for IBS-D expected in the third quarter of 2017."

The patent applications, entitled 'Antiemetic Extended Release Solid Dosage Forms' and 'Ondansetron Extended Release Solid Dosage Forms for Treating Either Nausea, Vomiting or Diarrhea Symptoms', cover claims directed to ondansetron extended release tablets and methods of treating patients with ondansetron extended release solid dosage forms. In addition to the two new U.S. patent applications, the patent portfolio covering BEKINDA® includes one U.S. patent, two pending U.S. patent applications, 17 foreign patents, and over 35 pending foreign patent applications. 

BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal indications. BEKINDA® is intended to provide patients with relief from nausea and vomiting symptoms for a full 24-hour period with a single oral tablet.

Top-line results from the Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017. In February 2017, RedHill announced that the last patient had completed the treatment course and observation period in the randomized, double-blind, placebo-controlled GUARD study, which treated 320 adults and children over the age of 12 in 29 U.S. clinical sites.

A randomized, double-blind, placebo-controlled Phase II study with BEKINDA® 12 mg is currently ongoing for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The Phase II study is evaluating the safety and efficacy of BEKINDA® 12 mg in adults over the age of 18 with IBS-D in 16 clinical sites in the U.S. Top-line results are expected in the third quarter of 2017.

The Phase III GUARD study and Phase II study with BEKINDA® are registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies.

About BEKINDA ®  (RHB-102):
BEKINDA® is a proprietary, bimodal extended-release (24 hours) oral pill formulation of ondansetron, covered by several issued and pending patents. A Phase III clinical study of BEKINDA® 24 mg formulation for acute gastroenteritis and gastritis (the GUARD study) is ongoing in the U.S., with patient treatment course and observation period completed and top-line results expected in the second quarter of 2017. A Phase II study with BEKINDA® 12 mg formulation is ongoing in the U.S. for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) with top-line results expected in the third quarter of 2017.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for Donnatal® , a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, as well as an exclusive license agreement with Entera Health for EnteraGam® , a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill's clinical-stage pipeline includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and QIDP status for nontuberculous mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP). More information about the Company is available at: www.redhillbio.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to successfully market Donnatal® and EnteraGam®, (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company's expenses, future revenues capital requirements and the Company's needs for additional financing; (xiii) competitive companies and technologies within the Company's industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

1 BEKINDA® is an investigational new drug, not available for commercial distribution.

Company contact:
Adi Frish
Senior VP Business Development &
Licensing
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com

IR contact (U.S.):
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
Mnanus@troutgroup.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RedHill Biopharma Ltd. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock29.6.2017 00:47Pressmeddelande

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38,750,000. The offering is expected to close on or about July 5th, 2017, subject to customary closing conditions. Citigroup and Jefferies are acting as the book-running managers for the offering, and JMP Securities is acting as lead manager for the offering.   Minerva has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock, on the same terms and conditions. Minerva intends to use the net proceeds from the offering, together with its existing cash and investments, to fund part of th

Yandy.com Celebrates Baywatch Movie With Inspired-By Swim Collection28.6.2017 20:18Pressmeddelande

Yandy launches swim collection for domestic and international consumers PHOENIX, June 28, 2017 (GLOBE NEWSWIRE) -- Yandy.com, the leading online retailer of intimates, swimwear, and specialty apparel, announced today the top-performing swimsuits from its Baywatch ®  swimwear collection. To celebrate the film's U.S. release - Yandy.com produced, marketed and sold three swimwear designs inspired by looks worn by the movie's female lifeguard characters. The new Baywatch movie follows devoted lifeguard Mitch Buchannon (Dwayne Johnson) as he butts heads with a brash new recruit (Zac Efron). Together, they uncover a local criminal plot that threatens the future of the Bay. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d8a5-c973-4449-be85-6289c481671c Yandy's release of the Baywatch-inspired collection in May demonstrated an immediate interest among domestic consumers. No

Nasdaq's Directors Desk® and Boardvantage® to Introduce Board Assessments and Compliance Questionnaires28.6.2017 16:05Pressmeddelande

A Unique Collaboration between Nasdaq Corporate Solutions and the Center for Board Excellence NEW YORK and GREENSBORO, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Nasdaq Corporate Solutions, a business of Nasdaq, Inc. (Nasdaq:NDAQ), announced today a new partnership with The Center for Board Excellence (CBE), a provider of board assessments and compliance questionnaires. In the first phase of the partnership, Nasdaq Corporate Solutions will facilitate introductions for users of Directors Desk and Boardvantage - Nasdaq's board portal and meeting management solutions - to CBE's cloud-based corporate governance solutions including: board and committee assessments; director peer assessments; CEO and management evaluations; and directors' & officers' questionnaires. Later this year, the parties plan to offer an integrated workflow between Nasdaq's board portal solutions and CBE's EnGauge(TM) platform, making it even easier for users to elect to benefit fr

Datameer : Datameer Announces Industry-First Solution for Deploying AI to the Enterprise at Big Data Scale28.6.2017 15:00Pressmeddelande

New Datameer SmartAI democratizes data science within organizations by operationalizing deep learning models with enterprise scale and governance SAN FRANCISCO, June 28, 2017 (GLOBE NEWSWIRE) -- Furthering its mission to democratize data access within the enterprise, Datameer today unveiled SmartAI, an industry-first solution for operationalizing deep learning models directly within enterprise data lake environments securely and at scale. SmartAI finally allows enterprises to democratize data science, taking the deep learning work of data scientists from the lab to the business in production-ready scenarios that meet the big data security, governance and management standards IT requires. Now, business analysts can apply and execute trusted deep learning models against massive datasets from enterprise data lakes to drive better business outcomes. "With all the promise of data science and artificial intelligence, organizations have had difficulty delivering on its busi

Imperial Capital Hires Two Senior Sales Professionals Forming a Dedicated Convertible Institutional Sales Group28.6.2017 14:30Pressmeddelande

LOS ANGELES, June 28, 2017 (GLOBE NEWSWIRE) -- Imperial Capital Group, LLC ("Imperial Capital") announced today the hiring of James P. Kenney and Kevin Cadden, two senior institutional convertible sales professionals, forming a dedicated Convertible Sales Group, while adding to the franchise's continued credit sales & trading growth initiatives. The group will be responsible for expanding Imperial Capital's existing credit sales and trading business further into convertible products while working with a team of seasoned trading and research professionals to provide its institutional clients with valuable market color, trading ideas and excellent execution in both the fixed income and equity markets. "With the hiring of James and Kevin, we are able to provide our institutional clients with a team of veteran sales and trading professionals specializing in the convertible bond marketplace," said Tom Corcoran, President of Imperial Capital. "The team bri

AGF Management Limited Reports Strong Second Quarter 2017 Financial Results28.6.2017 14:00Pressmeddelande

30% growth in mutual fund gross sales compared to prior year quarter 50% of ranked AUM performed above median for the one-year period ended May 31, 2017, and 53% for the three-year period Achieved final close of InstarAGF Essential Infrastructure Fund (EIF) with $740 million in commitments Reported Diluted EPS of $0.16 compared to $0.12 in Q2 2016 TORONTO, June 28, 2017 (GLOBE NEWSWIRE) -- AGF Management Limited (AGF or the Company) today announced financial results for the second quarter ended May 31, 2017. Total assets under management (AUM) increased 8.0% to $36.4 billion compared to the same period in 2016, and up 3.7% compared to $35.1 billion as at February 28, 2017. AUM increased across all lines of business, including retail, private client, institutiona

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum